SCHEMBL3967152

SCHEMBL3967152

FC(F)(F)c1nccn1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.50
ALOX15B O15296 3/20 0.50
CYP3A4 P08684 5/20 0.42
CYP1A2 P05177 4/20 0.42
CYP2D6 P10635 4/20 0.42
CYP2C9 P11712 4/20 0.42
CYP2C19 P33261 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
FDPS P14324 1/20 0.41
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
CYP2E1 P05181 1/20 0.37
CYP2A6 P11509 1/20 0.37
NOTUM Q6P988 1/20 0.37
KDR P35968 2/20 0.36
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoline SCHEMBL27735527 0.86 ALDH1A1 (0.49) L3MBTL1ALOX15BCYP3A4CYP1A2CYP2D6
SCHEMBL25382278 0.83 NOTUM (0.39) L3MBTL1ALOX15BSMN1; SMN2GAAALDH1A1
SCHEMBL28003186 0.81 NR1I2 (0.48) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL28003240 0.81 MAPT (0.46) NOTUMFGFR1
SCHEMBL16843173 0.81 CYP3A4 (0.43) L3MBTL1ALOX15BCYP3A4CYP1A2CYP2D6
SCHEMBL28354722 0.78 NOTUM (0.42) L3MBTL1ALOX15BSMN1; SMN2NPC1RAB9A
SCHEMBL9080396 0.78 ALDH1A1 (0.45) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL27303560 0.78 CYP19A1 (0.43) CYP3A4
SCHEMBL8783801 0.78 ALOX15B (0.42) L3MBTL1ALOX15BCYP3A4CYP1A2CYP2D6
SCHEMBL26951482 0.76 CYP3A4 (0.36) L3MBTL1ALOX15BCYP3A4CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581309-A4 KINASE MODULATORS EXELIXIS INC (US) 2009-07-29 EP claimed
EP-1581309-A2 KINASE MODULATORS Exelixis, Inc. (US) 2005-10-05 EP claimed
WO-2004050681-A2 KINASE MODULATORS EXELIXIS, INC. (US) 2004-06-17 WO claimed
EP-3191449-A1 NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2017-07-19 EP disclosed
WO-2016037578-A1 NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-03-17 WO disclosed
CN-105209464-A P2x7 modulators JANSSEN PHARMACEUTICA NV 2015-12-30 CN disclosed
CN-101679297-B LXR and FXR modulators EXELIXIS INC 2012-01-11 CN disclosed
CN-101679297-A lxr and fxr modulators EXELIXIS INC 2010-03-24 CN disclosed
EP-1581309-A4 KINASE MODULATORS EXELIXIS INC (US) 2009-07-29 EP disclosed
EP-1581309-A2 KINASE MODULATORS Exelixis, Inc. (US) 2005-10-05 EP disclosed
CN-1668595-A Method for forming carbon-carbon or carbon-heteroatom bonds RHONE POULENC CHIMIE (FR) 2005-09-14 CN disclosed
WO-2004050681-A2 KINASE MODULATORS EXELIXIS, INC. (US) 2004-06-17 WO disclosed